“CORPORATE DIVERSIFICATION of companies such as Procordia AB has allowed well-hidden financial ties between pharmaceutical companies and the tobacco industry to foster collaboration among companies. . . . We argue that it is not an acceptable conflict of interest for a company to profit both from selling addictive tobacco products and the drugs to treat the addiction.”
http://www.medscape.com/viewarticle/786012
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022